|
1
|
Yung KW, Yung TT, Chung CY, Tong GT, Liu
Y, Henderson J, Welbeck D and Oseni S: Principles of cancer
staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
|
|
2
|
Kawasaki K, Kurahara K, Yanai S, Oshiro Y,
Yao T, Kobayashi H, Nakamura S, Fuchigami T, Sugai T and Matsumoto
T: Colonoscopic features and malignant potential of sessile
serrated adenomas: comparison with other serrated lesions and
conventional adenomas. Colorectal Dis. 18:795–802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson DH, Taylor WR, Aboelsoud MM, Foote
PH, Yab TC, Cao X, Smyrk TC, Loftus EV Jr, Mahoney DW, Ahlquist DA,
et al: DNA methylation and mutation of small colonic neoplasms in
ulcerative colitis and Crohn's colitis: implications for
surveillance. Inflamm Bowel Dis. 22:1559–1567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang HF, Wu CC, Sun CA, Chu CM, Lin FG,
Hsieh JF, Hsu CH, Huang CH, Yang T, Tsai YM, et al: Clinical stage
and risk of recurrence and mortality: interaction of DNA
methylation factors in patients with colorectal cancer. J Investig
Med. 13:17–18. 2016.
|
|
5
|
Guo YH, Wang LQ, Li B, Xu H, Yang JH,
Zheng LS, Yu P, Zhou AD, Zhang Y, Xie SJ, et al: Wnt/β-catenin
pathway transactivates microRNA-150 that promotes EMT of colorectal
cancer cells by suppressing CREB signaling. Oncotarget. Jun
7–2016.(Epub ahead of print).
|
|
6
|
Bae JM, Lee TH, Cho NY, Kim TY and Kang
GH: Loss of CDX2 expression is associated with poor prognosis in
colorectal cancer patients. World J Gastroenterol. 21:1457–1467.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mutoh H, Hayakawa H, Sakamoto H and Sugano
K: Homeobox protein CDX2 reduces Cox-2 transcription by
inactivating the DNA-binding capacity of nuclear factor-kappaB. J
Gastroenterol. 42:719–729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizoshita T, Tsukamoto T, Nakanishi H,
Inada K, Ogasawara N, Joh T, Itoh M, Yamamura Y and Tatematsu M:
Expression of Cdx2 and the phenotype of advanced gastric cancers:
relationship with prognosis. J Cancer Res Clin Oncol. 129:727–734.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee MS, McGuffey EJ, Morris JS, Manyam G,
Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang
ZQ, et al: Association of CpG island methylator phenotype and
EREG/AREG methylation and expression in colorectal cancer. Br J
Cancer. 114:1352–1361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang JF, Qu LS, Qian XF, Xia BL, Mao ZB
and Chen WC: Nuclear transcription factor CDX2 inhibits gastric
cancer cell growth and reverses epithelial to mesenchymal
transition in vitro and in vivo. Mol Med Rep.
12:5231–5238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dawson H, Galván JA, Helbling M, Muller
DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A and
Zlobec I: Possible role of Cdx2 in the serrated pathway of
colorectal cancer characterized by BRAF mutation, high-level CpG
island methylator phenotype and mismatch repair-deficiency. Int J
Cancer. 134:2342–2351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kawai H, Tomii K, Toyooka S, Yano M,
Murakami M, Tsukuda K and Shimizu N: Promoter methylation
downregulates CDX2 expression in colorectal carcinomas. Oncol Rep.
13:547–551. 2005.PubMed/NCBI
|
